Zymeworks Gelecekteki Büyüme
Future kriter kontrolleri 6/6
Zymeworks kazanç ve gelirin sırasıyla yıllık 36.1% ve 21% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 42.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 42.9% olacağı tahmin edilmektedir.
Anahtar bilgiler
36.1%
Kazanç büyüme oranı
42.40%
EPS büyüme oranı
| Biotechs kazanç büyümesi | 28.8% |
| Gelir büyüme oranı | 21.0% |
| Gelecekteki özkaynak getirisi | 42.88% |
| Analist kapsamı | Good |
| Son güncelleme | 09 Sep 2026 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Anlatı Güncellemesi • Sep 03
ZYME: FDA Ziihera Milestones Will Drive Future Oncology Upside
Analysts have raised their fair value estimate for Zymeworks from $55.28 to $59.89, following a series of price target increases that reflect recent FDA approvals for Ziihera regimens, the Theravance royalty deal, and a broader set of contracted milestone and cash flow opportunities. Analyst Commentary Bullish analysts are broadly positive on Zymeworks, with recent notes highlighting how FDA approvals for Ziihera regimens, the Theravance royalty deal, and partner progress could support the company’s valuation and execution story.Seeking Alpha • Aug 27
Zymeworks: Transitioning Into A Royalty-Driven Biopharma Platform Post Ziihera Approval
Summary Zymeworks Inc. is transitioning from a development-stage biotech to a royalty-driven, revenue-generating platform following zanidatamab’s FDA approval. Zanidatamab’s first-line HER2+ gastroesophageal cancer approval expands the eligible patient population and unlocks a $250M milestone plus 10–20% tiered royalties. ZYME’s near-term upside hinges on commercial execution, label expansions, and integrating durable cash-flow assets like YUPELRI from the pending Theravance acquisition. Valuation reflects expectations of a step change in revenue and cash flow, with the market pricing in both transition potential and execution risk. Read the full article on Seeking Alpha
Anlatı Güncellemesi • Jul 20
ZYME: Theravance Acquisition And Royalty Expansion Will Drive Future Upside Narrative
Zymeworks' analyst fair value estimate has increased from $28.00 to $31.00 as analysts incorporate updated earnings models, account for the fuller impact of the Theravance Biopharma acquisition, and consider a more active sector catalyst calendar that supports the revised price targets across recent research. Analyst Commentary Recent research on Zymeworks points to a more constructive stance on the stock, with several firms updating models to reflect the Theravance Biopharma acquisition and a busier sector catalyst calendar.Anlatı Güncellemesi • Jul 06
ZYME: Royalty Deal And ADC Progress Will Shape Balanced Outlook
Analysts have raised their average price target on Zymeworks to $37, a $3 increase that they attribute to the Theravance Biopharma acquisition. They view the deal as adding durable royalty cash flows and aligning well with Zymeworks' internal development capabilities.
Anlatı Güncellemesi • Jun 22
ZYME: Ovarian Cancer Data And Fast Track Status Will Drive Repricing
Zymeworks’ updated analyst price target has edged down from about $40.08 to $39.23. Analysts point to revised assumptions on long term revenue growth, profit margins, and future P/E as key drivers of the change.Analiz Makalesi • Jun 21
Zymeworks (ZYME) Stock Could Be 42.3% Undervalued After Cryo EM Breakthrough
Why Zymeworks’ Cryo‑EM Breakthrough Matters for the Stock Zymeworks (ZYME) just reported a collaboration with Gandeeva Therapeutics that used high resolution cryo electron microscopy to map a small antigen bound to a Zymeworks antibody, sharpening insight into antibody epitope binding. For you as a shareholder or potential investor, the key point is that this work goes beyond a headline partnership announcement and delivers specific structural data, including a 2.6 Å view of nine amino acids...Anlatı Güncellemesi • Jun 05
ZYME: Royalty Deal And FDA Milestones Will Support Oncology Upside
Analysts have increased their price target on Zymeworks to $48 from $33, citing the recent $250m Royalty Pharma debt deal as a key support for slightly higher projected revenue growth, modestly stronger profit margins, and a lower future P/E assumption in their updated model. Analyst Commentary Recent research points to improving confidence around Zymeworks, with bullish analysts highlighting the Royalty Pharma debt deal and its impact on financial flexibility and valuation assumptions.Anlatı Güncellemesi • May 15
ZYME: Royalty-Focused Model And 2026 Oncology Milestones Will Drive Upside
Narrative Update on Zymeworks Analysts have nudged their outlook on Zymeworks higher, with recent price target moves to $46, $47 and $48 framed around the $250m Royalty Pharma debt deal and a greater focus on royalty income, even as updated assumptions now reflect modestly lower fair value alongside higher discount rates, revenue growth, profit margin and a reduced future P/E multiple. Analyst Commentary Bullish analysts are clustering around a similar message for Zymeworks, with recent research tying higher price targets to the US$250m Royalty Pharma debt deal and a clearer tilt toward royalty income.Anlatı Güncellemesi • Apr 29
ZYME: Royalty Model Shift Will Rely On Upcoming HER2 Gastric Trial Data
Narrative Update on Zymeworks Analysts have lifted Zymeworks' implied price target range into the mid to high $40s, citing the $250m Royalty Pharma debt deal and a shift toward a more royalty focused model as key reasons for refining assumptions around profitability and a higher future P/E multiple. Analyst Commentary Recent Street research has been broadly constructive on Zymeworks, with several price target increases clustered in the mid to high $40s.Anlatı Güncellemesi • Apr 14
ZYME: Royalty Model Outlook Will Hinge On Upcoming HER2 Gastric Cancer Data
Analysts have raised Zymeworks’ fair value estimate from about $36.46 to $40.08, citing higher price targets in the $46 to $48 range, supportive views on the $250m Royalty Pharma financing, and a shift toward a more royalty-focused business model. Analyst Commentary Recent Street research has focused on Zymeworks’ financing decisions, its pivot toward a royalty-driven model, and the pipeline events that could influence how investors think about execution and valuation.Anlatı Güncellemesi • Mar 31
ZYME: Royalty Model Shift And FY26 Catalysts Will Drive Future Upside
Analysts have lifted their Zymeworks price target range into the mid $40s, citing the $250m Royalty Pharma financing and the company's tilt toward a more royalty-focused model, along with upcoming clinical and R&D milestones, as key supports for the higher valuations. Analyst Commentary Bullish analysts are clustering around price targets in the mid US$40s, reflecting a view that the recent US$250m Royalty Pharma financing and the pivot toward royalties could support higher valuations if execution stays on track.Anlatı Güncellemesi • Mar 17
ZYME: Royalty Model Shift And Debt Deal Will Drive Future Upside
Narrative Update: Zymeworks Analyst Price Target Shift The analyst price target for Zymeworks has moved from $48.27 to $55.34, with analysts pointing to the recent $250m Royalty Pharma debt deal, a more royalty-focused model, and upcoming clinical and R&D milestones as key factors supporting the higher valuation range cited in recent reports of $46 to $48. Analyst Commentary Bullish analysts are leaning into a more constructive view on Zymeworks, with several price targets now clustered in the mid to high US$40s range.Anlatı Güncellemesi • Mar 03
ZYME: Cancer Trial Success And Royalty Potential Will Drive Future Upside
Analysts have raised their price target on Zymeworks from $42.00 to approximately $48.27, citing updated assumptions around revenue growth, profit margins and future P/E expectations. What's in the News Chief Financial and Business Officer Leone Patterson plans to leave Zymeworks in the first quarter of 2026, with her role ending January 9, 2026, and employment concluding January 31, 2026 (company announcement).Anlatı Güncellemesi • Feb 17
ZYME: Royalty Model Will Be Supported By Upcoming HER2 Gastric Cancer Data
Analysts have raised their price targets on Zymeworks, with one firm moving to $40 from $37 and another to $25 from $17, citing the company's shift toward a royalty-focused model and expectations around upcoming HERIZON GEA-01 data as key drivers. Analyst Commentary Bullish Takeaways Bullish analysts point to the shift toward a royalty-focused model as a key reason for higher price targets, arguing that recurring royalty streams can support more visible revenue over time.Yeni Anlatı • Feb 11
ADC And T Cell Engager Setbacks Will Test Reliance On Milestones Yet Offer Long-Term Upside
Catalysts About Zymeworks Zymeworks is a clinical stage biotechnology company focused on antibody drug conjugates, T cell engagers and partnered biologics for oncology and inflammatory diseases. What are the underlying business or industry changes driving this perspective?Anlatı Güncellemesi • Feb 03
ZYME: Royalty Model Will Be Driven By Positive HER2 Gastric Cancer Data
Narrative Update Analysts have nudged their blended price target for Zymeworks higher from about $34.50 to roughly $35.62 as they factor in the company’s shift toward a royalty-focused model around zani, positive HERIZON-GEA data for Ziihera, and updated views on future profitability and P/E assumptions. Analyst Commentary Street research on Zymeworks is clustering around two main themes: the shift toward a royalty-focused model centered on zani, and the impact of recent clinical data for Ziihera and early pipeline assets.Anlatı Güncellemesi • Jan 19
ZYME: Royalty Model And Cancer Data Will Drive Future Upside
Analysts have lifted their price targets on Zymeworks into a US$25 to US$42 range, citing the shift toward a royalty-focused model, positive HERIZON-GEA-01 data for Ziihera and Zani, and early but encouraging readouts for ZW191 and ZW251 as key drivers of their updated views. Analyst Commentary Bullish analysts are reacting positively to Zymeworks' shift toward a royalty-focused model and the recent clinical updates for Ziihera, Zani, ZW191, and ZW251.Anlatı Güncellemesi • Jan 05
ZYME: Royalty Aggregator Model And Cancer Data Will Drive Future Upside
Analysts have lifted their price targets on Zymeworks into a roughly US$25 to US$42 range, reflecting their views on the company’s shift toward a royalty-focused model, positive HERIZON-GEA-01 data around Ziihera and Zani, and early ZW191 results that feed into higher assumed profit margins and a richer future P/E multiple in updated models. Analyst Commentary Recent Street research on Zymeworks has been broadly constructive, with several firms revisiting their models after the shift toward a royalty-focused setup and fresh clinical data around Ziihera, Zani and ZW191.Anlatı Güncellemesi • Dec 18
ZYME: Royalty Model And Cancer Data Will Drive Share Outperformance
The analyst fair value estimate for Zymeworks has been raised from $30.00 to $42.00 per share, as analysts point to stronger than expected HERIZON-GEA-01 efficacy data, an expanding royalty-driven model, and upgraded Street price targets as key drivers of higher growth and margin assumptions. Analyst Commentary Bullish analysts are increasingly framing Zymeworks as a higher quality growth story, citing a transition toward a recurring, royalty-driven revenue model and stronger than expected efficacy data from HERIZON GEA-01.Anlatı Güncellemesi • Dec 04
ZYME: Royalty Model Will Benefit From Positive HER2 Gastric Cancer Data
Analysts nudged their fair value estimate for Zymeworks slightly higher, from $34.20 to $34.50. This reflects growing confidence that the company’s shift toward a royalty aggregator model, coupled with strong HERIZON-GEA-01 data for Ziihera and encouraging early ZW191 results, can drive faster revenue growth and improved profitability.Anlatı Güncellemesi • Nov 20
ZYME: Recurring Royalty Revenue Will Drive Momentum After Positive Clinical Results
Zymeworks' analyst price target has surged from approximately $24.45 to $34.20 per share. This increase reflects analysts' optimism following the company's positive clinical trial results and strategic shift toward generating recurring royalty revenues.Analiz Makalesi • Nov 18
Zymeworks Inc.'s (NASDAQ:ZYME) Shares Climb 30% But Its Business Is Yet to Catch Up
Despite an already strong run, Zymeworks Inc. ( NASDAQ:ZYME ) shares have been powering on, with a gain of 30% in the...Analiz Makalesi • Nov 09
Zymeworks Inc. (NASDAQ:ZYME) Just Released Its Third-Quarter Earnings: Here's What Analysts Think
It's been a mediocre week for Zymeworks Inc. ( NASDAQ:ZYME ) shareholders, with the stock dropping 14% to US$16.46 in...Anlatı Güncellemesi • Nov 05
ZYME: Encouraging Pipeline Data Will Drive Momentum Ahead Of Key Clinical Readouts
Analysts have raised their price target for Zymeworks from $23.68 to $24.45 per share. They cite increased confidence in the company's growth outlook following encouraging clinical data and expanding therapeutic opportunities.Anlatı Güncellemesi • Oct 22
Analysts Raise Zymeworks Target on Pipeline Progress While Weighing Risks and Valuation Changes
Analysts have increased their price target for Zymeworks from $21.45 to $23.68 per share. They cite the company's differentiated therapies and upcoming clinical milestones as key drivers for the revised outlook.Anlatı Güncellemesi • Oct 08
Oncology And Biologic Therapies Will Unlock Global Opportunities
Analysts have increased their price target for Zymeworks from $20.06 to $21.45, citing improving revenue growth forecasts, stronger projected profit margins, and growing confidence in the momentum of Zanidatamab in biliary tract cancer. Analyst Commentary Recent commentary from street research reflects a mix of optimism and caution surrounding Zymeworks, particularly as the company advances its lead asset, Zanidatamab, in the biliary tract cancer market.Anlatı Güncellemesi • Sep 20
Oncology And Biologic Therapies Will Unlock Global Opportunities
Despite raised analyst confidence driven by positive clinical momentum for Zanidatamab and anticipated catalysts, Zymeworks’ consensus analyst price target has been modestly lowered from $21.05 to $20.06. Analyst Commentary Positive momentum for Zanidatamab in biliary tract cancer.Analiz Makalesi • Sep 07
Optimistic Investors Push Zymeworks Inc. (NASDAQ:ZYME) Shares Up 25% But Growth Is Lacking
The Zymeworks Inc. ( NASDAQ:ZYME ) share price has done very well over the last month, posting an excellent gain of...Analiz Makalesi • Aug 10
Zymeworks Inc. Just Reported A Surprise Profit And Analysts Updated Their Estimates
Last week, you might have seen that Zymeworks Inc. ( NASDAQ:ZYME ) released its second-quarter result to the market...Analiz Makalesi • Jun 18
There's Reason For Concern Over Zymeworks Inc.'s (NASDAQ:ZYME) Price
There wouldn't be many who think Zymeworks Inc.'s ( NASDAQ:ZYME ) price-to-sales (or "P/S") ratio of 9.1x is worth a...Analiz Makalesi • May 14
Analysts Just Shipped A Stunning Upgrade To Their Zymeworks Inc. (NASDAQ:ZYME) Estimates
Zymeworks Inc. ( NASDAQ:ZYME ) shareholders will have a reason to smile today, with the analysts making substantial...Seeking Alpha • Apr 28
Zymeworks: Poised For Growth With Platform Validation
Summary Zymeworks' FDA approval of Ziihera for HER2-positive biliary tract cancer validates its science, partnerships, and positions it for long-term value creation. Financial stability is evident with $76.3 million in revenue in 2024 and a cash runway extending through late 2027. The robust pipeline includes zanidatamab for additional indications and promising early-stage candidates like ZW171 and ZW209 targeting high-unmet need cancers. Competitive landscape and clinical risks exist, but Zymeworks' innovative biologics and strategic partnerships make it a compelling biotech investment. Read the full article on Seeking AlphaAnaliz Makalesi • Apr 16
We're Hopeful That Zymeworks (NASDAQ:ZYME) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2028 | 239 | 14 | 62 | 84 | 7 |
| 12/31/2027 | 353 | 89 | 109 | 123 | 8 |
| 12/31/2026 | 304 | 121 | 100 | 105 | 8 |
| 6/30/2026 | 37 | -150 | -121 | -119 | N/A |
| 3/31/2026 | 81 | -103 | -78 | -75 | N/A |
| 12/31/2025 | 106 | -81 | -35 | -33 | N/A |
| 9/30/2025 | 134 | -63 | -66 | -64 | N/A |
| 6/30/2025 | 123 | -74 | -41 | -39 | N/A |
| 3/31/2025 | 93 | -114 | -79 | -76 | N/A |
| 12/31/2024 | 76 | -123 | -113 | -110 | N/A |
| 9/30/2024 | 62 | -114 | -59 | -55 | N/A |
| 6/30/2024 | 63 | -113 | -96 | -91 | N/A |
| 3/31/2024 | 50 | -126 | -77 | -73 | N/A |
| 12/31/2023 | 76 | -119 | -122 | -118 | N/A |
| 9/30/2023 | 462 | 205 | 192 | 195 | N/A |
| 6/30/2023 | 448 | 186 | 159 | 165 | N/A |
| 3/31/2023 | 446 | 173 | 108 | 116 | N/A |
| 12/31/2022 | 412 | 124 | 131 | 144 | N/A |
| 9/30/2022 | 30 | -224 | -252 | -234 | N/A |
| 6/30/2022 | 32 | -237 | -231 | -212 | N/A |
| 3/31/2022 | 28 | -240 | -224 | -207 | N/A |
| 12/31/2021 | 27 | -212 | -206 | -192 | N/A |
| 9/30/2021 | 22 | -211 | -199 | -190 | N/A |
| 6/30/2021 | 21 | -223 | -161 | -155 | N/A |
| 3/31/2021 | 31 | -194 | -161 | -155 | N/A |
| 12/31/2020 | 39 | -181 | -158 | -151 | N/A |
| 9/30/2020 | 25 | -215 | -147 | -140 | N/A |
| 6/30/2020 | 30 | -173 | -150 | -135 | N/A |
| 3/31/2020 | 26 | -163 | N/A | -98 | N/A |
| 12/31/2019 | 30 | -145 | N/A | -82 | N/A |
| 9/30/2019 | 57 | -64 | N/A | 5 | N/A |
| 6/30/2019 | 51 | -52 | N/A | 3 | N/A |
| 3/31/2019 | 65 | -29 | N/A | 20 | N/A |
| 12/31/2018 | 53 | -37 | N/A | 24 | N/A |
| 9/30/2018 | 74 | -13 | N/A | 13 | N/A |
| 6/30/2018 | 72 | -11 | N/A | 14 | N/A |
| 3/31/2018 | 52 | -16 | N/A | -5 | N/A |
| 12/31/2017 | 52 | -11 | N/A | 0 | N/A |
| 9/30/2017 | 4 | -55 | N/A | -47 | N/A |
| 6/30/2017 | 6 | -51 | N/A | -50 | N/A |
| 3/31/2017 | 11 | -47 | N/A | -41 | N/A |
| 12/31/2016 | 11 | -34 | N/A | -35 | N/A |
| 9/30/2016 | 10 | -30 | N/A | -32 | N/A |
| 12/31/2015 | 10 | -19 | N/A | -22 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: ZYME önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 3.7% ) daha hızlı bir büyüme olarak değerlendiriliyor.
Kazançlar ve Piyasa: ZYME önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.
Yüksek Büyüme Kazançları: ZYME önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.
Gelir ve Pazar: ZYME şirketinin gelirinin (yıllık 21% ) US pazarından (yıllık 13.5% ) daha hızlı büyümesi öngörülüyor.
Yüksek Büyüme Geliri: ZYME şirketinin gelirinin (yıllık 21% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: ZYME 'nin Özsermaye Getirisi'nin 3 yıl içinde çok yüksek olması tahmin ediliyor ( 42.9 %).
Büyüyen şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/09/10 12:29 |
| Gün Sonu Hisse Fiyatı | 2026/09/10 00:00 |
| Kazançlar | 2026/06/30 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Zymeworks Inc. 21 Bu analistlerden 8, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Tania Armstrong-Whitworth | ATB Cormark Historical (Cormark Securities) |
| David Martin | Bloom Burton & Co. |
| Mayank Mamtani | B. Riley Securities, Inc. |